AstraZeneca Proposes USD 1.5 Billion Manufacturing Facility

AstraZeneca, a pharmaceutical firm, expects to construct a $1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), upgrading the worldwide stockpile of its ADC portfolio. ADCs are cutting-edge therapies that potent cancer-killing agents straightforwardly to cancer growth cells through a designated immunizer. 

The arranged Greenfield office, upheld by the Singapore Economic Development Board (EDB), will be AstraZeneca's first end-to-end ADC creation site, completely integrating all means of the manufacturing system at a business scale. Manufacturing ADCs is a multi-step process that involves the creation of an immune response, the union of chemotherapy drugs and linkers, forming medication linkers to the immunizer and filling the finished ADC substance.

Png Cheong Boon, chairman, EDB said: "We welcome AstraZeneca's decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer. This Greenfield investment is a strong show of confidence in Singapore's biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with AstraZeneca."

Pascal Soriot, chief executive officer, AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”